Epix/Schering gain European approval for Vasovist MRA (magnetic resonance angiography) contrast agent
This article was originally published in Clinica
Executive Summary
Epix Pharmaceuticals has made its market debut after gaining European clearance for Vasovist - the first imaging agent specifically designed for magnetic resonance angiography (MRA). Epix' worldwide marketing partner, Schering, says it expects to commercialise the product in all 25 member states of the EU by early 2006.